SALR Stock Overview
Engages in the provision of distribution, promotion, active sales, and value-added services for the medicinal products in Slovenia and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
SALUS, Ljubljana, d. d. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2,000.00 |
| 52 Week High | €2,080.00 |
| 52 Week Low | €1,540.00 |
| Beta | 0.46 |
| 11 Month Change | 0% |
| 3 Month Change | 0.50% |
| 1 Year Change | 29.03% |
| 33 Year Change | 50.38% |
| 5 Year Change | 198.51% |
| Change since IPO | 2,270.68% |
Recent News & Updates
Recent updates
SALUS Ljubljana d. d (LJSE:SALR) Is Due To Pay A Dividend Of €35.00
Mar 14
SALUS, Ljubljana, d. d.'s (LJSE:SALR) 28% Price Boost Is Out Of Tune With Earnings
Feb 06SALUS Ljubljana d. d (LJSE:SALR) Will Pay A Dividend Of €35.00
Dec 30SALUS Ljubljana d. d (LJSE:SALR) Has Announced A Dividend Of €35.00
Apr 05We Think You Should Be Aware Of Some Concerning Factors In SALUS Ljubljana d. d's (LJSE:SALR) Earnings
Mar 22SALUS Ljubljana d. d (LJSE:SALR) Has Announced A Dividend Of €35.00
Mar 12SALUS Ljubljana d. d (LJSE:SALR) Has A Pretty Healthy Balance Sheet
Sep 21We Like These Underlying Return On Capital Trends At SALUS Ljubljana d. d (LJSE:SALR)
Jun 02With EPS Growth And More, SALUS Ljubljana d. d (LJSE:SALR) Is Interesting
May 13These 4 Measures Indicate That SALUS Ljubljana d. d (LJSE:SALR) Is Using Debt Reasonably Well
Apr 22Shareholders Of SALUS Ljubljana d. d (LJSE:SALR) Must Be Happy With Their 274% Total Return
Mar 17Are Strong Financial Prospects The Force That Is Driving The Momentum In SALUS, Ljubljana, d. d.'s LJSE:SALR) Stock?
Feb 12
The Price Is Right For SALUS, Ljubljana, d. d. (LJSE:SALR)
Jan 26There's A Lot To Like About SALUS Ljubljana d. d's (LJSE:SALR) Upcoming €25.00 Dividend
Jan 07SALUS Ljubljana d. d (LJSE:SALR) Seems To Use Debt Rather Sparingly
Dec 24How Does SALUS, Ljubljana, d. d. (LJSE:SALR) Fare As A Dividend Stock?
Dec 02Shareholder Returns
| SALR | SI Healthcare | SI Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | -0.02% |
| 1Y | 29.0% | 7.2% | 35.1% |
Return vs Industry: SALR exceeded the SI Healthcare industry which returned 7.2% over the past year.
Return vs Market: SALR underperformed the SI Market which returned 35.1% over the past year.
Price Volatility
| SALR volatility | |
|---|---|
| SALR Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 4.1% |
| Market Average Movement | 2.5% |
| 10% most volatile stocks in SI Market | 3.4% |
| 10% least volatile stocks in SI Market | 1.7% |
Stable Share Price: SALR's share price has been volatile over the past 3 months compared to the SI market.
Volatility Over Time: Insufficient data to determine SALR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 582 | Ziga Hieng | www.salus.si |
SALUS, Ljubljana, d. d. engages in the provision of distribution, promotion, active sales, and value-added services for the medicinal products in Slovenia and internationally. The company offers medicines, medical devices, diagnostic devices, medical supplies, sanitary products, dietary supplements, cosmetic products, pharmaceutical packaging’s, and other health and well-being related products to pharmacies, hospitals, community health centers, residential homes, veterinary institutions, and other customers. It also provides distribution, storage and transport, destruction, medicine authentication, and secondary packing services; pharmacoeconomic services; pharmacovigilance and medical device vigilance services; marketing communication services; and specialized and regulatory services.
SALUS, Ljubljana, d. d. Fundamentals Summary
| SALR fundamental statistics | |
|---|---|
| Market cap | €210.75m |
| Earnings (TTM) | €13.02m |
| Revenue (TTM) | €642.28m |
16.2x
P/E Ratio0.3x
P/S RatioIs SALR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SALR income statement (TTM) | |
|---|---|
| Revenue | €642.28m |
| Cost of Revenue | €571.28m |
| Gross Profit | €71.00m |
| Other Expenses | €57.97m |
| Earnings | €13.02m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 123.61 |
| Gross Margin | 11.05% |
| Net Profit Margin | 2.03% |
| Debt/Equity Ratio | 0% |
How did SALR perform over the long term?
See historical performance and comparison